TABLE 1.

Observed polymorphisms in F₄₂₀ genes and MIC values of delamanid^a

Patient no. or reference	Lineage	Country	HIV status	Age (yr) at TB diagnosis	Gender	Mutation(s) in the F420 genes	Treatment outcome	MIC (mg/liter) in the microdilution
Reference	H37Rv (ATCC 27294)					Control (wt)		≤0.015
1	L4.1.2.1	Côte d’Ivoire	Negative	29	Female	fgd1 Lys270Met	Cured	0.5
2	L4.6.2.2	Côte d’Ivoire	Negative	51	Male	ddn C168T	Died	≤0.015
3	L2.2.1	Kenya	Positive	40	Male	fgd1 T960C	Died	≤0.015
4	L2.2.1	Peru	Positive	28	Male	fgd1 T960C	Unknown	≤0.015
5	L4.3.2	Peru	Negative	21	Male	fbiC C1161T	Cured	≤0.015
6	L4.1.2.1	Peru	Positive	45	Male	fgd1 Lys270Met	Unknown	0.03
7	L4.1.2.1	Peru	Positive	36	Male	fbiC G-11A, fgd1 Lys270Met	Unknown	≤0.015
8	L4.1.2	South Africa	Negative	57	Female	fbiA Ile208Val	Cured	≤0.015
9	L2.2.1	Thailand	Unknown	76	Male	fgd1 T960C, ddn 85-87del (Tyr29del)	Died	>8
10	L1.1.1	Thailand	Negative	42	Male	fbiC Ala416Val Trp678Gly, fgd1 Arg64Ser T960C	Unknown	0.03

^aAll patients were treated with 2 months of daily isoniazid, rifampin, pyrazinamide, and ethambutol, followed by 4 months of daily rifampin and isoniazid. Data for isolates for which the MIC was >0.015 are shown in boldface. wt, wild type; L, lineage.